The company has opened its Qualified Institutions Placement (QIP) issue on November 13. The floor price has been fixed at Rs ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...

Shares of AstraZeneca PLC AZN rallied 1.54% to £101.44 Wednesday, on what proved to be an all-around favorable trading ...

The FTSE 100 index is seen opening eight points higher at 8034, having fallen 1.2% to a three-month low in yesterday’s ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens gave his rating based on several factors, including AstraZeneca’s ...

Stock Advisor returns as of November 11 ... including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. All ...

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...